Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
Jun 4, 2026, 16:17Nada Fahd: Immune Thrombocytopenia (ITP) – Outpatient vs Inpatient Management
-
Jun 4, 2026, 16:16Saoud Hassan: Hemostasis and Blood Coagulation Pathway – Simplified
-
Jun 4, 2026, 16:15Farooq Khan: Vacuuming Blood Clots in Seconds
-
Jun 4, 2026, 16:14Kayla Garrett: Confirming Or Excluding APS Relies On Accurate Lupus Anticoagulant Testing
-
Jun 4, 2026, 16:14Scott Colton: Exploring the Key Differences Between Anticoagulant and Antiplatelet Medications
-
Jun 4, 2026, 16:13Wolfgang Miesbach: Is Bone Health a Silent Comorbidity In Haemophilia and VWD?
-
Jun 4, 2026, 15:35Carolina La Mura: Insights from the LATAM Hemophilia Forum 2026
-
Jun 4, 2026, 15:25Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia